Intranasal sumatriptan: in adolescents with migraine

Area of Science:

• Neurology
• Pharmacology

Background:

• Sumatriptan, a selective serotonin 5-HT(1B/1D) receptor agonist, is known to constrict cranial blood vessels and modulate neuroinflammatory pathways.
• These mechanisms are relevant to migraine pathophysiology.

Purpose of the Study:

• To evaluate the efficacy and tolerability of intranasal sumatriptan in adolescent migraineurs.
• To assess both immediate and sustained headache relief following administration.

Main Methods:

• A well-designed study assessed a single 10 mg dose of oral sumatriptan in adults.
• Two pooled studies evaluated single doses of intranasal sumatriptan (20 mg and 5 mg) in adolescents compared to placebo.
• Adolescents were assessed for headache relief at various time points and tolerability.

Main Results:

• A single 10 mg oral dose of sumatriptan demonstrated significant headache relief at 1 hour compared to placebo in adults.
• Intranasal sumatriptan (20 mg and 5 mg) resulted in significantly more headache relief at 1 and 2 hours post-dose in adolescents versus placebo.
• Sustained headache relief (1-24 and 2-24 hours) was significantly improved with intranasal sumatriptan in adolescents.
• Intranasal sumatriptan was generally well-tolerated, with taste disturbance being the most frequent adverse event.

Conclusions:

• Sumatriptan is an effective treatment for acute migraine headaches in adolescents.
• Intranasal sumatriptan offers a viable therapeutic option for adolescent migraineurs, providing both rapid and sustained relief.
• The safety profile of intranasal sumatriptan in adolescents is favorable, although taste disturbances should be noted.